<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The present study addresses the neuroprotective function of intracerebroventricular (i.c.v.) application of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>, a selective ligand of the peroxisome proliferator-activated receptor gamma (PPARgamma) in the rat brain after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> or vehicle were i.c.v. infused via osmotic minipumps over a 5-day period before, and 2 days after transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) for 90 min </plain></SENT>
<SENT sid="2" pm="."><plain>This i.c.v. application of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> in the brain significantly reduced the <z:mpath ids='MPATH_124'>infarct</z:mpath> size and <z:hpo ids='HP_0002181'>brain oedema</z:hpo>, and attenuated in the peri-<z:mpath ids='MPATH_124'>infarct</z:mpath> cortical regions the invasion of activated microglia and macrophages </plain></SENT>
<SENT sid="3" pm="."><plain>Moreover, <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> improved the recovery of <z:e sem="disease" ids="C0748618" disease_type="Disease or Syndrome" abbrv="">sensory deficits</z:e> 48 h after MCAO </plain></SENT>
<SENT sid="4" pm="."><plain>Our data demonstrate for the first time that it is the activation of intracerebral PPARgamma that can confer neuroprotection, anti-inflammatory and neurological improvement following ischaemic injury </plain></SENT>
</text></document>